Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges

Seminars in Cancer Biology

Volumn 40_41, Issue , 2016, Pages 82-99

  Shankar, Eswar ^a,b   Kanwal, Rajnee ^a,b   Candamo, Mario ^c   Gupta, Sanjay ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer chemoprevention; Dietary agents; DNA methylation; Epigenetics; Histone modification; microRNA; Plant polyphenols

Indexed keywords

3 INDOLEMETHANOL; 3,3' DIINDOLYLMETHANE; APIGENIN; CURCUMIN; DNA; EPIGALLOCATECHIN GALLATE; GENISTEIN; ISOFLAVONE DERIVATIVE; LYCOPENE; ORGANOSULFUR DERIVATIVE; PHENETHYL ISOTHIOCYANATE; PLANT MEDICINAL PRODUCT; POLYPHENOL DERIVATIVE; QUERCETIN; RESVERATROL; SULFORAPHANE; UNTRANSLATED RNA; ANTINEOPLASTIC AGENT;

CANCER PREVENTION; DIET; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; NONHUMAN; REVIEW; SOYBEAN; TEA; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; NEOPLASM; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DIET; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PHYTOCHEMICALS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84975691111     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2016.04.002     Document Type: Review

References (258)

1. [1] Henikoff, S., Matzke, M.A., Exploring and explaining epigenetic effects. Trends Genet. 13 (1997), 293–295.
2. [2] Hughes, V., Epigenetics: the sins of the father. Nature 507 (2014), 22–24.
3. [3] Payer, B., Lee, J.T., X chromosome dosage compensation: how mammals keep the balance. Annu. Rev. Genet. 42 (2008), 733–772.
4. [4] Illingworth, R., Kerr, A., DeSousa, D., Jørgensen, H., Ellis, P., Stalker, J., et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol., 6, 2008, e22.
5. [5] Li, E., Beard, C., Jaenisch, R., Role for DNA methylation in genomic imprinting. Nature 366 (1993), 362–365.
6. [6] Jones, P.A., Takai, D., The role of DNA methylation in mammalian epigenetics. Science 293 (2001), 1068–1070.
7. [7] Jarome, T.J., Lubin, F.D., Histone lysine methylation: critical regulator of memory and behavior. Rev. Neurosci. 24 (2013), 375–387.
8. [8] Peixoto, L., Abel, T., The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology 38 (2013), 62–76.
9. [9] Lubin, F.D., Gupta, S., Parrish, R.R., Grissom, N.M., Davis, R.L., Epigenetic mechanisms: critical contributors to long-term memory formation. Neuroscientist 17 (2011), 616–632.
10. [10] Gos, M., Epigenetic mechanisms of gene expression regulation in neurological diseases. Acta Neurobiol. Exp. (Wars) 73 (2013), 19–37.
11. [11] Jones, P.A., Baylin, S.B., The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3 (2002), 415–428.
12. [12] Stilling, R.M., Fischer, A., The role of histone acetylation in age-associated memory impairment and Alzheimer's disease. Neurobiol. Learn Mem. 96 (2011), 19–26.
13. [13] Bruce, K.D., Cagampang, F.R., Epigenetic priming of the metabolic syndrome. Toxicol Mech Methods 21 (2011), 353–361.
14. [14] Suter, M.A., Aagaard-Tillery, K.M., Environmental influences on epigenetic profiles. Semin. Reprod. Med. 27 (2009), 380–390.
15. [15] Jaenisch, R., Bird, A., Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33 (2003), 245–254.
16. [16] Choudhuri, S., From Waddington's epigenetic landscape to small noncoding RNA: some important milestones in the history of epigenetics research. Toxicol. Mech. Methods 21 (2011), 252–274.
17. [17] Issa, J.P., Kantarjian, H.M., Targeting DNA methylation. Clin. Cancer Res. 15 (2009), 3938–3946.
18. [18] Dehan, P., Kustermans, G., Guenin, S., Horion, J., Boniver, J., Delvenne, P., DNA methylation and cancer diagnosis: new methods and applications. Exp. Rev. Mol. Diagn. 9 (2009), 651–657.
19. [19] Link, A., Balaguer, F., Goel, A., Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol. 80 (2010), 1771–1792.
20. [20] Gerhauser, C., Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. Top Curr. Chem. 329 (2013), 73–132.
21. [21] Bestor, T.H., The DNA methyltransferases of mammals. Hum. Mol. Genet. 9 (2000), 2395–2402.
22. [22] Santi, D.V., Garrett, C.E., Barr, P.J., On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 33 (1983), 9–10.
23. [23] Bird, A., DNA methylation patterns and epigenetic memory. Genes Dev. 16 (2002), 6–21.
24. [24] Yoder, J.A., Soman, N.S., Verdine, G.L., Bestor, T.H., DNA (cytosine-5)-methyltransferases in mouse cells and tissues: studies with a mechanism-based probe. J. Mol. Biol. 270 (1997), 385–395.
25. [25] Okano, M., Bell, D.W., Haber, D.A., Li, E., DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999), 247–257.
26. [26] Bourc'his, D., Xu, G.L., Lin, C.S., Bollman, B., Bestor, T.H., Dnmt3L and the establishment of maternal genomic imprints. Science 294 (2001), 2536–2539.
27. [27] Hata, K., Okano, M., Lei, H., Li, E., Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development 129 (2002), 1983–1993.
28. [28] Denis, H., Ndlovu, M.N., Fuks, F., Regulation of mammalian DNA methyltransferases: a route to new mechanisms. EMBO Rep. 12 (2011), 647–656.
29. [29] Watt, F., Molloy, P.L., Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 2 (1988), 1136–1143.
30. [30] Hark, A.T., Schoenherr, C.J., Katz, D.J., Ingram, R.S., Levorse, J.M., Tilghman, S.M., CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405 (2000), 486–489.
31. [31] Tate, P.H., Bird, A.P., Effects of DNA methylation on DNA-binding proteins and gene expression. Curr. Opin. Genet Dev. 3 (1993), 226–231.
32. [32] Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., Landsberger, N., et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19 (1998), 187–191.
33. [33] Nan, X., Ng, H.H., Johnson, C.A., Laherty, C.D., Turner, B.M., Eisenman, R.N., et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393 (1998), 386–389.
34. [34] Feng, Q., Zhang, Y., The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 15 (2001), 827–832.
35. [35] Hendrich, B., Bird, A., Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol. Cell. Biol. 18 (1998), 6538–6547.
36. [36] Nan, X., Meehan, R.R., Bird, A., Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. Nucliic Acids Res. 21 (1993), 4886–4892.
37. [37] Roos, L., Van Dongen, J., Bell, C.G., Burri, A., Deloukas, P., Boomsma, D.I., et al. Integrative DNA methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairs. Clin. Epigenetics., 8, 2016, 7.
38. [38] Bhat, S., Kabekkodu, S.P., Noronha, A., Satyamoorthy, K., Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie 121 (2016), 298–311.
39. [39] Yen, C.Y., Huang, H.W., Shu, C.W., Hou, M.F., Yuan, S.F., Wang, H.R., et al. DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers. Cancer Lett. 373 (2016), 185–192.
40. [40] Luger, K., Richmond, T.J., The histone tails of the nucleosome. Curr. Opin Genet Dev. 8 (1998), 140–146.
41. [41] Kornberg, R.D., Lorch, Y., Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98 (1999), 285–294.
42. [42] Strahl, B.D., Allis, C.D., The language of covalent histone modifications. Nature 403 (2000), 41–45.
43. [43] Struhl, K., Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12 (1998), 599–606.
44. [44] Bannister, A.J., Kouzarides, T., Regulation of chromatin by histone modifications. Cell Res. 21 (2011), 381–395.
45. [45] Kuo, M.H., Allis, C.D., Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 20 (1998), 615–626.
46. [46] Sauve, A.A., Wolberger, C., Schramm, V.L., Boeke, J.D., The biochemistry of sirtuins. Annu. Rev. Biochem. 75 (2006), 435–465.
47. [47] Mottet, D., Castronovo, V., Histone deacetylases: target enzymes for cancer therapy. Clin. Exp. Metastasis 25 (2008), 183–189.
48. [48] Shi, Y., Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet. 8 (2007), 829–833.
49. [49] Rice, J.C., Allis, C.D., Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr. Opin. Cell Biol. 13 (2001), 263–273.
50. [50] Upadhyay, A.K., Cheng, X., Dynamics of histone lysine methylation: structures of methyl writers and erasers. Prog. Drug Res. 67 (2011), 107–124.
51. [51] Mir, A.R., Moinuddin Islam, S., Circulating autoantibodies in cancer patients have high specificity for glycoxidation modified histone H2A. Clin. Chim. Acta. 453 (2016), 48–55.
52. [52] Ma, F., Zhang, C.Y., Histone modifying enzymes: novel disease biomarkers and assay development. Expert Rev. Mol. Diagn. 11 (2016), 1–10.
53. [53] Deb, G., Singh, A.K., Gupta, S., EZH2: not EZHY (Easy) to deal. Mol. Cancer Res. 12 (2014), 639–653.
54. [54] Kouzarides, T., Chromatin modifications and their function. Cell 128 (2007), 693–705.
55. [55] Suzuki, T., Miyata, N., Epigenetic control using natural products and synthetic molecules. Curr. Med. Chem. 13 (2006), 935–958.
56. [56] Costa, F.F., Non-coding RNAs, epigenetics and complexity. Gene 410 (2008), 9–17.
57. [57] Peschansky, V.J., Wahlestedt, C., Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics 9 (2014), 3–12.
58. [58] Zhou, H., Hu, H., Lai, M., Non-coding RNAs and their epigenetic regulatory mechanisms. Biol. Cell. 102 (2010), 645–655.
59. [59] Mattick, J.S., Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep. 2 (2001), 986–991.
60. [60] Szymanski, M., Barciszewska, M.Z., Erdmann, V.A., Barciszewski, J., A new frontier for molecular medicine: noncoding RNAs. Biochim. Biophys. Acta 1756 (2005), 65–75.
61. [61] Deb, G., Thakur, V.S., Gupta, S., Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics 8 (2013), 464–476.
62. [62] Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H.A., Barth, T.F., et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 112 (2008), 4202–4212.
63. [63] Varambally, S., Cao, Q., Mani, R.S., Shankar, S., Wang, X., Ateeg, B., et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322 (2008), 1695–1699.
64. [64] Juan, A.H., Kumar, R.M., Marx, J.G., Young, R.A., Sartorelli, V., Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol. Cell. 36 (2009), 61–74.
65. [65] Liu, S., Tetzlaff, M.T., Cui, R., Xu, X., miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am. J. Pathol. 181 (2012), 1823–1835.
66. [66] Godlewski, J., Nowicki, M.O., Bronisz, A., Williams, S., Otsuki, A., Nuovo, G., et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 68 (2008), 9125–9130.
67. [67] Liz, J., Esteller, M., lncRNAs and microRNAs with a role in cancer development. Biochim. Biophys. Acta 1859 (2016), 169–176.
68. [68] Fabris, L., Ceder, Y., Chinnaiyan, A.M., Jenster, G.W., Sorensen, K.D., Tomlins, S., et al. The potential of MicroRNAs as prostate cancer biomarkers. Eur. Urol., 2016 pii: S0302-2838(16)00012-9.
69. [69] Wellner, U., Schubert, J., Burk, U.C., Schmalhofer, O., Zhu, F., Sonntag, A., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11 (2009), 1487–1495.
70. [70] Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 15805–15810.
71. [71] Garzon, R., Liu, S., Fabbri, M., Liu, Z., Heaphy, C.E., Callegari, E., et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113 (2009), 6411–6418.
72. [72] Huang, J., Plass, C., Gerhauser, C., Cancer chemoprevention by targeting the epigenome. Curr. Drug Targets. 12 (2011), 1925–1956.
73. [73] Russo, G.L., Vastolo, V., Ciccarelli, M., Albano, L., Macchia, P.E., Ungaro, P., Dietary polyphenols and chromatin remodelling. Crit. Rev. Food Sci. Nutr., 10(September), 2015 (Epub ahead of print).
74. [74] Thakur, V.S., Deb, G., Babcook, M.A., Gupta, S., Plant phytochemicals as epigenetic modulators: role in cancer chemoprevention. AAPS J. 16 (2014), 151–163.
75. [75] Hauser, A.T., Jung, M., Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med. 74 (2008), 1593–1601.
76. [76] Davis, C.D., Ross, S.A., Evidence for dietary regulation of microRNA expression in cancer cells. Nutr. Rev. 66 (2008), 477–482.
77. [77] Li, Y., Kong, D., Wang, Z., Sarkar, F.H., Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm. Res. 27 (2010), 1027–1041.
78. [78] Patel, D., Shukla, S., Gupta, S., Apigenin and cancer chemoprevention: progress, potential and promise (review). Int. J. Oncol. 30 (2007), 233–245.
79. [79] Birt, D.F., Hendrich, S., Wang, W., Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol. Ther. 90 (2001), 157–177.
80. [80] Surh, Y.J., Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 3 (2003), 768–780.
81. [81] Manach, C., Scalbert, A., Morand, C., Rémésy, C., Jiménez, L., Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 79 (2004), 727–747.
82. [82] Birt, D.F., Walker, B., Tibbels, M.G., Bresnick, E., Anti-mutagenesis and anti-promotion by apigenin, robinetin and indole-3-carbinol. Carcinogenesis 7 (1986), 959–963.
83. [83] Wei, H., Tye, L., Bresnick, E., Birt, D.F., Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res. 50 (1990), 499–502.
84. [84] Choi, J.S., Islam, M.N., Ali, M.Y., Kim, E.J., Kim, Y.M., Jung, H.A., Effects of C-glycosylation on anti-diabetic, anti-Alzheimer's disease and anti-inflammatory potential of apigenin. Food Chem. Toxicol. 64 (2014), 27–33.
85. [85] Fang, M., Chen, D., Yang, C.S., Dietary polyphenols may affect DNA methylation. J. Nutr. 137 (2007), 223s–228s.
86. [86] Pandey, M., Kaur, P., Shukla, S., Abbas, A., Fu, P., Gupta, S., Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: in vitro and in vivo study. Mol. Carcinog. 51 (2012), 952–962.
87. [87] Paredes-Gonzalez, X., Fuentes, F., Su, Z.Y., Kong, A.N., Apigenin reactivates Nrf2 anti-oxidative stress signaling in mouse skin epidermal JB6 P+ cells through epigenetics modifications. AAPS J. 16 (2014), 727–735.
88. [88] Prasad, S., Gupta, S.C., Tyagi, A.K., Aggarwal, B.B., Curcumin a component of golden spice: from bedside to bench and back. Biotechnol. Adv. 32 (2014), 1053–1064.
89. [89] Bar-Sela, G., Epelbaum, R., Schaffer, M., Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr. Med. Chem. 17 (2010), 190–197.
90. [90] Sharma, R.A., Gescher, A.J., Steward, W.P., Curcumin: the story so far. Eur. J. Cancer. 41 (2005), 1955–1968.
91. [91] Teiten, M.H., Eifes, S., Dicato, M., Diederich, M., Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins (Basel) 2 (2010), 128–162.
92. [92] Fu, S., Kurzrock, R., Development of curcumin as an epigenetic agent. Cancer 116 (2010), 4670–4676.
93. [93] Medina-Franco, J.L., Lopez-Vallejo, F., Kuck, D., Lyko, F., Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol. Divers 15 (2011), 293–304.
94. [94] Liu, Z., Xie, Z., Jones, W., Pavlovicz, R.E., Liu, S., Yu, J., et al. Curcumin is a potent DNA hypomethylation agent. Bioorg Med. Chem. Lett. 19 (2009), 706–709.
95. [95] Bora-Tatar, G., Dayangac-Erden, D., Demir, A.S., Dalkara, S., Yelekçi, K., Erdem-Yurter, H., Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies. Bioorg Med. Chem. 17 (2009), 5219–5228.
96. [96] Liu, H.L., Chen, Y., Cui, G.H., Zhou, J.F., Curcumin a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol. Sin. 26 (2005), 603–609.
97. [97] Chen, Y., Shu, W., Chen, W., Wu, Q., Liu, H., Cui, G., Curcumin, both histone deacetylase and p300/CBP-specific inhibitor, represses the activity of nuclear factor kappa B and Notch 1 in Raji cells. Basic Clin. Pharmacol. Toxicol. 101 (2007), 427–433.
98. [98] Dekker, F.J., Haisma, H.J., Histone acetyl transferases as emerging drug targets. Drug Discov. Today 14 (2009), 942–948.
99. [99] Marcu, M.G., Jung, Y.J., Lee, S., Chung, E.J., Lee, M.J., Trepel, J., et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem. 2 (2006), 169–174.
100. [100] Balasubramanyam, K., Varier, R.A., Altaf, M., Swaminathan, V., Siddappa, N.B., Ranga, U., et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279 (2004), 51163–51171.
101. [101] Guo, Y., Shu, L., Zhang, C., Su, Z.Y., Kong, A.N., Curcumin inhibits anchorage-independent growth of HT29 human colon cancer cells by targeting epigenetic restoration of the tumor suppressor gene DLEC1. Biochem. Pharmacol. 9 (2015), 69–78.
102. [102] Sharma, V., Jha, A.K., Kumar, A., Bhatnagar, A., Narayan, G., Kaur, J., Curcumin-Mediated reversal of p15 gene promoter methylation: implication in anti-Neoplastic action against acute lymphoid leukaemia cell line. Folia Biol. (Praha) 61 (2015), 81–89.
103. [103] Sun, M., Estrov, Z., Ji, Y., Coombes, K.R., Harris, D.H., Kurzrock, R., Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 7 (2008), 464–473.
104. [104] Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiak, K., Schaffert, J.M., et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res. 70 (2010), 3606–3617.
105. [105] Jiang, A., Wang, X., Shan, X., Li, Y., Wang, P., Jiang, P., Feng, Q., Curcumin reactivates silenced tumor suppressor gene RARβ by reducing DNA methylation. Phytother. Res. 29 (2015), 1237–1245.
106. [106] Zamani, M., Sadeghizadeh, M., Behmanesh, M., Najafi, F., Dendrosomal curcumin increases expression of the long non coding RNA gene MEG3 via up-regulation of epi-miRs in hepatocellular cancer. Phytomedicine 22 (2015), 961–967.
107. [107] Butt, M.S., Sultan, M.T., Green tea: nature's defense against malignancies. Crit. Rev. Food Sci. Nutr. 49 (2009), 463–473.
108. [108] Shankar, S., Ganapathy, S., Srivastava, R.K., Green tea polyphenols: biology and therapeutic implications in cancer. Front. Biosci. 12 (2007), 4881–4899.
109. [109] Fang, M.Z., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., et al. Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63 (2003), 7563–7570.
110. [110] Pandey, M., Shukla, S., Gupta, S., Promoter demethylation and chromatin remodeling by green tea polyphenols leads to re-expression of GSTP1 in human prostate cancer cells. Int. J. Cancer. 126 (2010), 2520–2533.
111. [111] Thakur, V.S., Gupta, K., Gupta, S., Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis 33 (2012), 377–784.
112. [112] Li, Y., Yuan, Y.Y., Meeran, S.M., Tollefsbol, T.O., Synergistic epigenetic reactivation of estrogen receptor-alpha (ERalpha) by combined green tea polyphenol and histone deacetylase inhibitor in ERalpha-negative breast cancer cells. Mol. Cancer, 9, 2010, 274.
113. [113] Nandakumar, V., Vaid, M., Katiyar, S.K., (−)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cells. Carcinogenesis 32 (2011), 537–544.
114. [114] Balasubramanian, S., Adhikary, G., Eckert, R.L., The Bmi-1 polycomb protein antagonizes the (−)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis 31 (2010), 496–503.
115. [115] Choudhury, S.R., Balasubramanian, S., Chew, Y.C., Han, B., Marquez, V.E., Eckert, R.L., (−)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis 32 (2011), 1525–1532.
116. [116] Deb, G., Thakur, V.S., Limaye, A.M., Gupta, S., Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells. Mol. Carcinog. 54 (2014), 485–499.
117. [117] Khan, M.A., Hussain, A., Sundaram, M.K., Alalami, U., Gunasekera, D., Ramesh, L., et al. (−)-Epigallocatechin-3 gallate reverses the expression of various tumor suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol. Rep. 33 (2015), 1976–1984.
118. [118] Zhou, X.Q., Xu, X.N., Li, L., Ma, J.J., Zhen, E.M., Han, C.B., Epigallocatechin-3-gallate inhibits the invasion of salivary adenoid cystic carcinoma cells by reversing the hypermethylation status of the RECK gene. Mol. Med. Rep. 12 (2015), 6031–6036.
119. [119] Jha, M., Aggarwal, R., Jha, A.K., Shrivastava, A., Natural compounds DNA methyltransferase inhibitors in oral squamous cell carcinoma. Appl. Biochem. Biotechnol. 177 (2015), 577–594.
120. [120] Chen, L.L., Han, W.F., Geng, Y., Su, J.S., A genome-wide study of DNA methylation modified by epigallocatechin-3-gallate in the CAL-27 cell line. Mol. Med. Rep. 12 (2015), 5886–5890.
121. [121] Coward, L., Barnes, N.C., Setchell, K.D.R., Barnes, S., Genistein, daidzein, and their β-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J. Agric. Food Chem. 41 (1993), 1961–1967.
122. [122] Kaufman, P.B., Duke, J.A., Brielmann, H., Boik, J., Hoyt, J.E., A comparative survey of leguminous plants as sources of the isoflavones, genistein and daidzein: implications for human nutrition and health. J. Altern. Complement Med. 3 (1997), 7–12.
123. [123] Banerjee, S., Li, Y., Wang, Z., Sarkar, F.H., Multi-targeted therapy of cancer by genistein. Cancer Lett. 269 (2008), 226–242.
124. [124] Fang, M.Z., Chen, D., Sun, Y., Jin, Z., Christman, J.K., Yang, C.S., Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 11 (2005), 7033–7041.
125. [125] Li, Y., Liu, L., Andrews, L.G., Tollefsbol, T.O., Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int. J. Cancer 125 (2009), 286–296.
126. [126] King-Batoon, A., Leszczynska, J.M., Klein, C.B., Modulation of gene methylation by genistein or lycopene in breast cancer cells. Environ. Mol. Mutagen 49 (2008), 36–45.
127. [127] Majid, S., Dar, A.A., Ahmad, A.E., Hirata, H., Kawakami, K., Shahryari, V., et al. BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer. Carcinogenesis 30 (2009), 662–670.
128. [128] Majid, S., Dar, A.A., Shahryari, V., Hirata, H., Ahmad, A., Saini, S., et al. Genistein reverses hypermethylation and induces active histone modifications in tumor suppressor gene B-Cell translocation gene 3 in prostate cancer. Cancer 116 (2010), 66–76.
129. [129] Day, J.K., Bauer, A.M., DesBordes, C., Zhuang, Y., Kim, B.E., Newton, L.G., et al. Genistein alters methylation patterns in mice. J. Nutr. 132 (2002), 2419–2423.
130. [130] Hong, T., Nakagawa, T., Pan, W., Kim, M.Y., Kraus, W.L., Ikehara, T., et al. Isoflavones stimulate estrogen receptor-mediated core histone acetylation. Biochem. Biophys. Res. Commun. 317 (2004), 259–264.
131. [131] Majid, S., Kikuno, N., Nelles, J., Noonan, E., Tanaka, Y., Kawamoto, K., et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 68 (2008), 2736–2744.
132. [132] Basak, S., Pookot, D., Noonan, E.J., Dahiya, R., Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol. Cancer Ther. 7 (2008), 3195–3202.
133. [133] Karsli-Ceppioglu, S., Ngollo, M., Adjakly, M., Dagdemir, A., Judes, G., Lebert, A., et al. Genome-wide DNA methylation modified by soy phytoestrogens: role for epigenetic therapeutics in prostate cancer?. OMICS 19 (2015), 209–219.
134. [134] Mahmoud, A.M., Al-Alem, U., Ali, M.M., Bosland, M.C., Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation. J. Steroid Biochem. Mol. Biol. 152 (2015), 62–75.
135. [135] Qin, W., Zhu, W., Shi, H., Hewett, J.E., Ruhlen, R.L., MacDonald, R.S., et al. Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women. Nutr. Cancer 61 (2009), 238–244.
136. [136] Parker, L.P., Taylor, D.D., Kesterson, J., Metzinger, D.S., Gercel-Taylor, C., Modulation of microRNA associated with ovarian cancer cells by genistein. Eur. J. Gynaecol. Oncol. 30 (2009), 616–621.
137. [137] Li, Y., VandenBoom, T.G., Kong, D., Wang, Z., Ali, S., Philip, P.A., et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69 (2009), 6704–6712.
138. [138] Sun, Q., Cong, R., Yan, H., Gu, H., Zeng, Y., Liu, N., et al. Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a and target gene expression. Oncol. Rep. 22 (2009), 563–567.
139. [139] Qin, J., Chen, J.X., Zhu, Z., Teng, J.A., Genistein inhibits human colorectal cancer growth and suppresses miR-95, Akt and SGK1. Cell Physiol. Biochem. 35 (2015), 2069–2077.
140. [140] Avci, C.B., Susluer, S.Y., Caglar, H.O., Balci, T., Aygunes, D., Dodurga, Y., et al. Genistein-induced mir-23b expression inhibits the growth of breast cancer cells. Contemp Oncol (Pozn) 19 (2015), 32–35.
141. [141] Rogan, E.G., The natural chemopreventive compound indole-3-carbinol: state of the science. In Vivo 20 (2006), 221–228.
142. [142] Minich, D.M., Bland, J.S., A review of the clinical efficacy and safety of cruciferous vegetable phytochemicals. Nutr. Rev. 65 (2007), 259–267.
143. [143] Acharya, A., Das, I., Singh, S., Saha, T., Chemopreventive properties of indole-3-carbinol, diindolylmethane and other constituents of cardamom against carcinogenesis. Recent Pat. Food Nutr. Agric. 2 (2010), 166–177.
144. [144] Aggarwal, B.B., Ichikawa, H., Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 4 (2005), 1201–1215.
145. [145] Banerjee, S., Kong, D., Wang, Z., Bao, B., Hillman, G.G., Sarkar, F.H., Attenuation of multi-targeted proliferation-linked signaling by 3,3′-diindolylmethane (DIM): from bench to clinic. Mutat. Res. 728 (2011), 47–66.
146. [146] Li, Y., Li, X., Guo, B., Chemopreventive agent 3,3′-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases. Cancer Res. 70 (2010), 646–654.
147. [147] Beaver, L.M., Yu, T.W., Sokolowski, E.I., Williams, D.E., Dashwood, R.H., Ho, E., 3,3′-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol. Appl. Pharmacol. 263 (2012), 345–351.
148. [148] Busbee, P.B., Nagarkatti, M., Nagarkatti, P.S., Natural indoles, indole-3-carbinol and 3,3'diindolymethane, inhibit T cell activation by staphylococcal enterotoxin B through epigenetic regulation involving HDAC expression. Toxicol. Appl. Pharmacol. 274 (2014), 7–16.
149. [149] Li, Y., Vandenboom, T.G., Wang, Z., Kong, D., Ali, S., Philip, P.A., et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70 (2010), 1486–1495.
150. [150] Jin, Y., Zou, X., Feng, X., 3,3′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells. Anticancer Drugs 21 (2010), 814–822.
151. [151] Wang, F., Li, S., Wang, L., Zong, H., Fan, Q., DATS suppresses growth of esophageal squamous cell carcinoma by regulation of ERK1/2. Clin. Lab. 61 (2015), 315–322.
152. [152] Chalabi, N., Satih, S., Delort, L., Bignon, Y.J., Bernard-Gallon, D.J., Expression profiling by whole-genome microarray hybridization reveals differential gene expression in breast cancer cell lines after lycopene exposure. Biochim. Biophys. Acta 1769 (2007), 124–130.
153. [153] Chalabi, N., Delort, L., Le Corre, L., Satih, S., Bignon, Y.J., Bernard-Gallon, D., Gene signature of breast cancer cell lines treated with lycopene. Pharmacogenomics 7 (2006), 663–672.
154. [154] Fu, L.J., Ding, Y.B., Wu, L.X., Wen, C.J., Qu, Q., Zhang, X., et al. The effects of lycopene on the methylation of the GSTP1 promoter and global methylation in prostatic cancer cell lines PC3 and LNCaP. Int. J. Endocrinol., 2014, 2014, 620165.
155. [155] Iciek, M., Kwiecien, I., Wlodek, L., Biological properties of garlic and garlic-derived organosulfur compounds. Environ. Mol. Mutagen. 50 (2009), 247–265.
156. [156] Nian, H., Delage, B., Ho, E., Dashwood, R.H., Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds. Environ. Mol. Mutagen. 50 (2009), 213–221.
157. [157] Lea, M.A., Randolph, V.M., Patel, M., Increased acetylation of histones induced by diallyl disulfide and structurally related molecules. Int. J. Oncol. 15 (1999), 347–352.
158. [158] Lea, M.A., Randolph, V.M., Lee, J.E., desBordes, C., Induction of histone acetylation in mouse erythroleukemia cells by some organosulfur compounds including allyl isothiocyanate. Int. J. Cancer. 92 (2001), 784–789.
159. [159] Lea, M.A., Rasheed, M., Randolph, V.M., Khan, F., Shareef, A., desBordes, C., Induction of histone acetylation and inhibition of growth of mouse erythroleukemia cells by S-allylmercaptocysteine. Nutr. Cancer 43 (2002), 90–102.
160. [160] Druesne, N., Pagniez, A., Mayeur, C., Thomas, M., Cherbuy, C., Duée, P.H., et al. Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 25 (2004), 1227–1236.
161. [161] Nian, H., Delage, B., Pinto, J.T., Dashwood, R.H., Allyl mercaptan a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter. Carcinogenesis 29 (2008), 1816–1824.
162. [162] Cheung, K.L., Kong, A.N., Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J. 12 (2010), 87–97.
163. [163] Wang, L.G., Beklemisheva, A., Liu, X.M., Ferrari, A.C., Feng, J., Chiao, J.W., Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol. Carcinog. 46 (2007), 24–31.
164. [164] Gibellini, L., Pinti, M., Nasi, M., Montagna, J.P., De Biasi, S., Roat, E., et al. Quercetin and cancer chemoprevention. Evid. Based Complement Alternat Med., 2011, 2011, 591356.
165. [165] Tan, S., Wang, C., Lu, C., Zhao, B., Cui, Y., Shi, X., et al. Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy 55 (2009), 6–10.
166. [166] Ruiz, P.A., Braune, A., Holzlwimmer, G., Quintanilla-Fend, L., Haller, D., Quercetin inhibits TNF-induced NF-kappaB transcription factor recruitment to proinflammatory gene promoters in murine intestinal epithelial cells. J. Nutr. 137 (2007), 1208–1215.
167. [167] Lee, W.J., Chen, Y.R., Tseng, T.H., Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol. Rep. 25 (2011), 583–591.
168. [168] Priyadarsini, R.V., Vinothini, G., Murugan, R.S., Manikandan, P., Nagini, S., The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors. Nutr. Cancer. 63 (2011), 218–226.
169. [169] Ravichandran, S., Singh, N., Donnelly, D., Migliore, M., Johnson, P., Fishwick, C., et al. Pharmacophore model of the quercetin binding site of the SIRT6 protein. J. Mol. Graph Model 49 (2014), 38–46.
170. [170] Singh, N., Ravichandran, S., Norton, D.D., Fugmann, S.D., Moaddel, R., Synthesis and characterization of a SIRT6 open tubular column: predicting deacetylation activity using frontal chromatography. Anal. Biochem. 436 (2013), 78–83.
171. [171] Kokkonen, P., Rahnasto-Rilla, M., Mellini, P., Jarho, E., Lahtela-Kakkonen, M., Kokkola, T., Studying SIRT6 regulation using H3K56 based substrate and small molecules. Eur. J. Pharm. Sci. 63 (2014), 71–76.
172. [172] Du, F., Feng, Y., Fang, J., Yang, M., MicroRNA-143 enhances chemosensitivity of Quercetin through autophagy inhibition via target GABARAPL1 in gastric cancer cells. Biomed. Pharmacother. 74 (2015), 169–177.
173. [173] Sonoki, H., Sato, T., Endo, S., Matsunaga, T., Yamaguchi, M., Yamazaki, Y., et al. Quercetin decreases claudin-2 expression mediated by up-Regulation of microRNA miR-16 in lung adenocarcinoma A549Cells. Nutrients 7 (2015), 4578–4592.
174. [174] Lou, G., Liu, Y., Wu, S., Xue, J., Yang, F., Fu, H., et al. The p53/miR-34a/SIRT1 positive feedback loop in quercetin induced apoptosis. Cell Physiol. Biochem. 35 (2015), 2192–2202.
175. [175] Zhang, X., Guo, Q., Chen, J., Chen, Z., Quercetin enhances cisplatin sensitivity of human osteosarcoma cells by modulating microRNA-217-KRAS axis. Mol. Cells 38 (2015), 638–642.
176. [176] Yang, F.Q., Liu, M., Li, W., Che, J.P., Wang, G.C., Zheng JH.Combination of quercetin and hyperoside inhibits prostate cancer cell growth and metastasis via regulation of microRNA-21. Mol. Med. Rep. 11 (2015), 1085–1092.
177. [177] Athar, M., Back, J.H., Kopelovich, L., Bickers, D.R., Kim, A.L., Multiple molecular targets of resveratrol: anti- carcinogenic mechanisms. Arch. Biochem. Biophys. 486 (2009), 95–102.
178. [178] Savouret, J.F., Quesne, M., Resveratrol and cancer: a review. Biomed. Pharmacother. 56 (2002), 84–87.
179. [179] Wang, R.H., Sengupta, K., Li, C., Kim, H.S., Cao, L., Xiao, C., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14 (2008), 312–323.
180. [180] Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood, J.G., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425 (2003), 191–196.
181. [181] Bishayee, A., Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila) 2 (2009), 409–418.
182. [182] Wood, J.G., Rogina, B., Lavu, S., Howitz, K., Helfand, S.L., Tatar, M., et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430 (2004), 686–689.
183. [183] Boily, G., He, X.H., Pearce, B., Jardine, K., McBurney, M.W., SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 28 (2009), 2882–2893.
184. [184] Wang, R.H., Zheng, Y., Kim, H.S., Xu, X., Cao, L., Luhasen, T., et al. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol. Cell. 32 (2008), 11–20.
185. [185] Kai, L., Samuel, S.K., Levenson, A.S., Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int. J. Cancer 126 (2010), 1538–1548.
186. [186] Kala, R., Shah, H.N., Martin, S.L., Tollefsbol, T.O., Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer. BMC Cancer, 15, 2015, 672.
187. [187] Wu, M.L., Li, H., Yu, L.J., Chen, X.Y., Kong, Q.Y., Song, X., et al. Shortterm resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS One, 9, 2014, e89806.
188. [188] Qin, W., Zhang, K., Clarke, K., Weiland, T., Sauter, E.R., Methylation and miRNA effects of resveratrol on mammary tumors vs normal tissue. Nutr. Cancer 66 (2014), 270–277.
189. [189] Papoutsis, A.J., Selmin, O.I., Borg, J.L., Romagnolo, D.F., Gestational exposure to the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring:Preventive effects of resveratrol. Mol. Carcinog. 54 (2015), 261–269.
190. [190] Azimi, A., Hagh, M.F., Talebi, M., Yousefi, B., Hossein Pour Feizi, A.A., Baradaran, B., et al. Time – and concentration – dependent effects of resveratrol on miR 15a and miR16-1Expression and apoptosis in the CCRF-CEM acute lymphoblastic leukemia cell line. Asian Pac. J. Cancer Prev. 16 (2015), 6463–6468.
191. [191] Dhar, S., Kumar, A., Rimando, A.M., Zhang, X., Levenson, A.S., Resveratrol and pterostilbene epigenetically restore PTEN expression by targeting oncomiRs of the miR-17 family in prostate cancer. Oncotarget 6 (2015), 27214–27226.
192. [192] Clarke, J.D., Dashwood, R.H., Ho, E., Multi-targeted prevention of cancer by sulforaphane. Cancer Lett. 269 (2008), 291–304.
193. [193] Tomczyk, J., Olejnik, A., Sulforaphane–a possible agent in prevention and therapy of cancer. Postepy Hig. Med. Dosw. 64 (2010), 590–603.
194. [194] Traka, M., Gasper, A.V., Smith, J.A., Hawkey, C.J., Bao, Y., Mithen, R.F., Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane. J. Nutr. 135 (2005), 1865–1872.
195. [195] Meeran, S.M., Patel, S.N., Tollefsbol, T.O., Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One, 5, 2010, e11457.
196. [196] Myzak, M.C., Karplus, P.A., Chung, F.L., Dashwood, R.H., A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 64 (2004), 5767–5774.
197. [197] Myzak, M.C., Hardin, K., Wang, R., Dashwood, R.H., Ho, E., Sulforaphane inhibits histone deacetylase activity in BpH −1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis 27 (2006), 811–819.
198. [198] Pledgie-Tracy, A., Sobolewski, M.D., Davidson, N.E., Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol. Cancer Ther. 6 (2007), 1013–1021.
199. [199] Wong, C.P., Hsu, A., Buchanan, A., Palomera-Sanchez, Z., Beaver, L.M., Andres Houseman E, et al Effects of sulforaphane and 3,3′-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. PLoS One, 9, 2014, e86787.
200. [200] Su, Z.Y., Zhang, C., Lee, J.H., Shu, L., Wu, T.Y., Khor, T.O., et al. Requirement and epigenetics reprogramming of Nrf2 in suppression of tumor promoter TPA-induced mouse skin cell transformation by sulforaphane. Cancer Prev. Res. 7 (2014), 319–329.
201. [201] Mileo, A.M., Miccadei, S., Polyphenols as modulator of oxidative stress in cancer disease: new therapeutic strategies. Oxid. Med. Cell. Longevity, 2016, 2016, 6475624, 10.1155/2016/6475624.
202. [202] Myzak, M.C., Dashwood, W.M., Orner, G.A., Ho, E., Dashwood, R.H., Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 20 (2006), 506–508.
203. [203] Myzak, M.C., Tong, P., Dashwood, W.M., Dashwood, R.H., Ho, E., Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp. Biol. Med. (Maywood) 232 (2007), 227–234.
204. [204] Lee, W.J., Shim, J.Y., Zhu, B.T., Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 68 (2005), 1018–1030.
205. [205] Huang, H.C., Way, T.D., Lin, C.L., Lin, J.K., EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein. Endocrinology 149 (2008), 5972–5983.
206. [206] Berletch, J.B., Liu, C., Love, W.K., Andrews, L.G., Katiyar, S.K., Tollefsbol, T.O., Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J. Cell Biochem. 103 (2008), 509–519.
207. [207] Navarro-Peran, E., Cabezas-Herrera, J., Campo, L.S., Rodriguez-Lopez, J.N., Effects of folate cycle disruption by the green tea polyphenol epigallocatechin-3-gallate. Int. J. Biochem. Cell Biol. 39 (2007), 2215–2225.
208. [208] Kato, K., Long, N.K., Makita, H., Toida, M., Yamashita, T., Hatakeyama, D., et al. Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. Br. J. Cancer. 99 (2008), 647–665.
209. [209] Tang, W.Y., Newbold, R., Mardilovich, K., Jefferson, W., Cheng, R.Y., Medvedovic, M., et al. Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp1) correlates with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. Endocrinology 149 (2008), 5922–5931.
210. [210] Fang, M.Z., Jin, Z., Wang, Y., Liao, J., Yang, G.Y., Wang, L.D., et al. Promoter hypermethylation and inactivation of O(6)-methylguanine-DNA methyltransferase in esophageal squamous cell carcinomas and its reactivation in cell lines. Int. J. Oncol. 26 (2005), 615–622.
211. [211] Vandegehuchte, M.B., Lemière, F., Vanhaecke, L., Vanden Berghe, W., Janssen, C.R., Direct and transgenerational impact on Daphnia magna of chemicals with a known effect on DNA methylation. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 151 (2010), 278–285.
212. [212] Paluszczak, J., Krajka-Kuźniak, V., Baer-Dubowska, W., The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol. Lett. 192 (2010), 119–125.
213. [213] Stefanska, B., Rudnicka, K., Bednarek, A., Fabianowska-Majewska, K., Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells. Eur. J. Pharmacol. 638 (2010), 47–53.
214. [214] Singh, N., Misra, K., Computational screening of molecular targets in Plasmodium for novel non-resistant anti-malarial drugs. Bioinformation 3 (2009), 255–262.
215. [215] Kang, J., Chen, J., Shi, Y., Jia, J., Zhang, Y., Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. Biochem. Pharmacol. 69 (2005), 1205–1213.
216. [216] Cui, L., Miao, J., Furuya, T., Li, X., Su, X.Z., Cui, L., PfGCN5-mediated histone H3 acetylation plays a key role in gene expression in Plasmodium falciparum. Eukaryot. Cell 6 (2007), 1219–1227.
217. [217] Sng, J.C., Taniura, H., Yoneda, Y., Histone modifications in kainate-induced status epilepticus. Eur. J. Neurosci. 23 (2006), 1269–1282.
218. [218] Chiu, J., Khan, Z.A., Farhangkhoee, H., Chakrabarti, S., Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-kappaB. Nutrition 25 (2009), 964–972.
219. [219] Tikoo, K., Meena, R.L., Kabra, D.G., Gaikwad, A.B., Change in post-translational modifications of histone H3, heat-shock protein-27 and MAP kinase p38 expression by curcumin in streptozotocin-induced type I diabetic nephropathy. Br. J. Pharmacol. 153 (2008), 1225–1231.
220. [220] Li, H.L., Liu, C., de Couto, G., Ouzounian, M., Sun, M., Wang, A.B., et al. Curcumin prevents and reverses murine cardiac hypertrophy. J. Clin. Invest. 118 (2008), 879–893.
221. [221] Morimoto, T., Sunagawa, Y., Kawamura, T., Takaya, T., Wada, H., Nagasawa, A., et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 118 (2008), 868–878.
222. [222] Liu, H.L., Chen, Y., Cui, G.H., Zhou, J.F., Curcumin a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol. Sin. 26 (2005), 603–609.
223. [223] Choi, K.C., Jung, M.G., Lee, Y.H., Yoon, J.C., Kwon, S.H., Kang, H.B., et al. Epigallocatechin-3-gallate, a histone acetyltransferase inhibitor, inhibits EBV-induced B lymphocyte transformation via suppression of RelA acetylation. Cancer Res. 69 (2009), 583–592.
224. [224] Lea, M.A., Randolph, V.M., Induction of histone acetylation in rat liver and hepatoma by organosulfur compounds including diallyl disulfide. Anticancer Res. 21 (2001), 2841–2845.
225. [225] Schwab, M., Reynders, V., Loitsch, S., Steinhilber, D., Schroder, O., Stein, J., The dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in intestinal epithelial cells. Immunology 125 (2008), 241–251.
226. [226] Hu, R., Khor, T.O., Shen, G., Jeong, W.S., Hebbar, V., Chen, C., et al. Cancer chemoprevention of intestinal polyposis in ApcMin/+ mice by sulforaphane, a natural product derived from cruciferous vegetable. Carcinogenesis 27 (2006), 2038–2046.
227. [227] Pledgie-Tracy, A., Sobolewski, M.D., Davidson, N.E., Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol. Cancer Ther. 6 (2007), 1013–1021.
228. [228] Chakrabarti, M., Khandkar, M., Banik, N.L., Ray, S.K., Alterations in expression of specific microRNAs by combination of 4-HPR and EGCG inhibited growth of human malignant neuroblastoma cells. Brain Res. 1454 (2012), 1–13.
229. [229] Chakrabarti, M., Banik, N.L., Ray, S.K., miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma in vitro and in vivo. Exp. Cell Res. 319 (2013), 1575–1585.
230. [230] Jiang, L., Huang, Q., Chang, J., Wang, E., Qiu, X., MicroRNA HSA-miR-125a-5p induces apoptosis by activating p53 in lung cancer cells. Exp. Lung Res. 37 (2011), 387–398.
231. [231] Saini, S., Arora, S., Majid, S., Shahryari, V., Chen, Y., Deng, G., et al. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer Prev. Res. (Phila.) 4 (2011), 1698–1709.
232. [232] Zhang, J., Du, Y., Wu, C., Ren, X., Ti, X., Shi, J., et al. Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186n signaling pathway. Oncol. Rep. 24 (2010), 1217–1223.
233. [233] Gao, S.M., Yang, J.J., Chen, C.Q., Chen, J.J., Ye, L.P., Wang, L.Y., et al. Pure curcumin decreases the expression of WT1 by upregulation of miR-15a and miR-16-1 in leukemic cells. J. Exp. Clin. Cancer Res., 31, 2012, 27.
234. [234] Sun, M., Estrov, Z., Ji, Y., Coombes, K.R., Harris, D.H., Kurzrock, R., et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 7 (2008), 464–473.
235. [235] Tsang, W.P., Kwok, T.T., Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J. Nutr. Biochem. 21 (2010), 140–146.
236. [236] Gandhy, S.U., Kim, K., Larsen, L., Rosengren, R.J., Safe, S., Curcumin and synthetic analogs induce reactive oxygen species and decreases specificity protein (Sp) transcription factors by targeting microRNAs. BMC Cancer, 12, 2012, 564.
237. [237] Jin, Y., 3,3′-Diindolylmethane inhibits breast cancer cell growth via miR-21-mediated Cdc25A degradation. Mol. Cell Biochem. 358 (2011), 345–354.
238. [238] Kong, D., Heath, E., Chen, W., Cher, M., Powell, I., Heilbrun, L., et al. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment. Am. J. Transl. Res. 4 (2012), 14–23.
239. [239] Melkamu, T., Zhang, X., Tan, J., Zeng, Y., Kassie, F., Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 31 (2010), 252–258.
240. [240] Ahn, J., Lee, H., Jung, C.H., Ha, T., Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol. Nutr. Food Res. 56 (2012), 1665–1674.
241. [241] Chiang, E.P., Chiu, S.C., Pai, M.H., Wang, Y.C., Wang, F.Y., Kuo, Y.H., et al. Organosulfur garlic compounds induce neovasculogenesis in human endothelial progenitor cells through a modulation of MicroRNA 221 and the PI3-K/Akt signaling pathways. J. Agric. Food Chem. 61 (2013), 4839–4849.
242. [242] Xiao, X., Chen, B., Liu, X., Liu, P., Zheng, G., Ye, F., et al. Diallyl disulfide suppresses SRC/Ras/ERK signaling-mediated proliferation and metastasis in human breast cancer by up-regulating miR-34a. PLoS One, 9, 2014, e112720.
243. [243] Dhar, S., Hicks, C., Levenson, A.S., Resveratrol and prostate cancer: promising role for microRNAs. Mol. Nutr. Food Res. 55 (2011), 1219–1229.
244. [244] Sheth, S., Jajoo, S., Kaur, T., Mukherjea, D., Sheehan, K., Rybak, L.P., et al. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One, 7, 2012, e51655.
245. [245] Tili, E., Michaille, J.J., Alder, H., Volinia, S., Delmas, D., Latruffe, N., Croce, C.M., Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFbeta signaling pathway in SW480 cells. Biochem. Pharmacol. 80 (2010), 2057–2065.
246. [246] Sakurai, M.A., Ozaki, Y., Okuzaki, D., Naito, Y., Sasakura, T., Okamoto, A., et al. Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS One, 9, 2014, e100124.
247. [247] Wu, H., Huang, M., Liu, Y., Shu, Y., Liu, P., Luteolin induces apoptosis by up-regulating miR-34a in human gastric cancer cells. Technol. Cancer Res. Treat. 14 (2015), 747–755.
248. [248] Xiao, J., Gong, A.Y., Eischeid, A.N., Chen, D., Deng, C., Young, C.Y., et al. miR-141modulates androgen receptor transcriptional activity in human prostate cancer cells through targeting the small heterodimer partner protein. Prostate 72 (2012), 1514–1522.
249. [249] Ide, H., Tokiwa, S., Sakamaki, K., Nishio, K., Isotani, S., Muto, S., et al. Combined inhibitory effects of soy isoflavones and curcumin on the production of prostate-specific antigen. Prostate 70 (2010), 1127–1133.
250. [250] Sharma, R.A., McLelland, H.R., Hill, K.A., Ireson, C.R., Euden, S.A., Manson, M.M., et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7 (2001), 1894–1900.
251. [251] Johnson, J.J., Bailey, H.H., Mukhtar, H., Green tea polyphenols for prostate cancer chemoprevention: a translational perspective. Phytomedicine 17 (2010), 3–13.
252. [252] Nguyen, M.M., Ahmann, F.R., Nagle, R.B., Hsu, C.H., Tangrea, J.A., Parnes, H.L., et al. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities. Cancer Prev. Res. 5 (2012), 290–298.
253. [253] Lazarevic, B., Hammarstrom, C., Yang, J., Ramberg, H., Diep, L.M., Karlsen, S.J., et al. The effects of short-term genistein intervention on prostate biomarker expression in patients with localised prostate cancer before radical prostatectomy. Br. J. Nutr. 108 (2012), 2138–2147.
254. [254] Miyanaga, N., Akaza, H., Hinotsu, S., Fujioka, T., Naito, S., Namiki, M., et al. Prostate cancer chemoprevention study: an investigative randomized control study using purified isoflavones in men with rising prostate-specific antigen. Cancer Sci. 103 (2012), 125–130.
255. [255] Heath, E.I., Heilbrun, L.K., Li, J., Vaishampayan, U., Harper, F., Pemberton, P., et al. A phase I dose-escalation study of oral BR-DIM in castrate-resistant, non-metastatic prostate cancer. Am. J. Transl. Res. 2 (2010), 402–411.
256. [256] Mariani, S., Lionetto, L., Cavallari, M., Tubaro, A., Rasio, D., De Nunzio, C., et al. Low prostate concentration of lycopene is associated with development of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. Int. J. Mol. Sci. 15 (2014), 1433–1440.
257. [257] Goldberg, D.M., Yan, J., Soleas, G.J., Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin. Biochem. 36 (2003), 79–87.
258. [258] Alumkal, J.J., Slottke, R., Schwartzman, J., Cherala, G., Munar, M., Graff, J.N., et al. A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Investig. New Drugs 33 (2015), 480–489.